Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

European Journal of Haematology

Volumn 97, Issue 3, 2016, Pages 297-302

  González López, Tomás José ^a   Alvarez Román, María Teresa ^b   Pascual, Cristina ^c   Sánchez González, Blanca ^d   Fernández Fuentes, Fernando ^e   Jarque, Isidro ^f   Pérez Rus, Gloria ^c   Pérez Crespo, Susana ^g   Bernat, Silvia ^h   Hernández Rivas, José Angel ⁱ   Andrade, Marcio M ^j   Cortés, Montserrat ^k   Gómez Nuñez, Marta ^l   Olivera, Pavel ^m   Martínez Robles, Violeta ⁿ   Fernández Rodríguez, Angeles ^o   Fuertes Palacio, Miguel Angel ^p   Fernández Miñano, Carmen ^q   de Cabo, Erik ^r   Fisac, Rosa ^s   Aguilar, Carlos ^t   Bárez, Abelardo ^u   Peñarrubia, María Jesús ^v   García Frade, Luis Javier ^w   González Porras, José Ramón ^x   more..

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g University Hospital of Santiago de Compostela   (Spain)

^h HOSPITAL DE LA PLANA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^k HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^l HOSPITAL DE SABADELL   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL DE LEÓN   (Spain)

^o HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^p HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^q HOSPITAL VEGA BAJA   (Spain)

^r HOSPITAL EL BIERZO   (Spain)

^s HOSPITAL GENERAL DE SEGOVIA   (Spain)

^t Hospital General del Insalud Soria   (Spain)

^u HOSPITAL PROVINCIAL DE ÁVILA   (Spain)

^v HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^w HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^x HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Immune; ITP; thrombocytopenia; thrombopoietin; TPO

Indexed keywords

CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; RETICULIN; RITUXIMAB;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; CHRONIC DISEASE; CHRONIC IMMUNE THROMBOCYTOPENIA; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEPATOBILIARY DISEASE; HEPATOBILIARY LABORATORY ABNORMALITY; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SUPERFICIAL VEIN THROMBOSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

EID: 84982128210     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12725     Document Type: Article

References (23)

1. Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011;152:52–60.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008.
3. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86.
4. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–207.
5. Sanz MA, Vicente García V, Fernández A, et al. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia. Med Clin (Barc) 2012;138:1–17.
6. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M; Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72–7.
7. Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med 2008;19:447–51.
8. Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 2013;91:236–41.
9. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901–12.
10. González-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015;169:111–6.
11. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47.
12. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–8.
13. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393–402.
14. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A, EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537–45.
15. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011;118:4338–45.
16. Gudbrandsdottir S, Frederiksen H, Hasselbalch H. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets 2012;23:423–9.
17. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93.
18. González-López TJ, Sánchez-González B, Pascual C, et al. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. Platelets 2015;26:83–6.
19. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015;90:E40–3.
20. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639–45.
21. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010;47:243–8.
22. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, Sørensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011;152:360–2.
23. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012;119:4066–72.